The Global Atopic Dermatitis Market Size is anticipated to gain traction due to increasing research and development for developing new drugs that would be an effective treatment for the atopic dermatitis.

Atopic dermatitis is persistent skin disease that affects large number of world’s population. It is an allergic hypersensitivity that is associated with inhalant allergies, and a chronic dermatitis. Commonly, atopic dermatitis is a hereditary component. It is diagnosed by appearance and distribution of rashes on the person’s body with the history of asthma. Atopic dermatitis is a non-contagious disease and can be identified by the swelling and redness on the skin. Atopic dermatitis occurs in all age groups but majorly affects infants and young children. Atopic dermatitis treatment involves the use of oral antibiotics, steroid pills, photo therapy, biological treatments like monoclonal antibody, and in some cases dietary changes that can cause food allergy.

Recently, various new drugs developed are referred as immune modulators. For instance, Dupilumab (Duxipent) was recently approved by the FDA for the treatment of severe atopic dermatitis in adults. It is an anti-IL-4 antibody that is injected in the patient’s body and has shown promising result in controlling atopic dermatitis. Hence, continuous new product development for treating atopic dermatitis has created new pace in atopic dermatitis market.

Increase in the new drug development as a novel treatment of atopic dermatitis is expected to boost the global atopic dermatitis market.

The global atopic dermatitis market size is primarily driven by increasing focus of the manufacturers on developing new products and partnerships with other companies to enable quicker approval and marketing of their products. Moreover, large untapped market with large number of target population, and increased preference for a single drug that would be able to cure two or more atopic dermatitis would also influence the atopic dermatitis market during the forecast period.

However, side effects associated with the use of drugs as a novel treatment could hinder the atopic dermatitis market growth. For example, the use of immunosuppressive drugs, like cyclosporine have shown side effects like high blood pressure, vomiting, kidney failure, headaches etc. Additionally, the high cost of newly developed biological drugs would also impede the global atopic dermatitis market size growth in coming years.

Global Atopic Dermatitis Market Taxonomy

The global atopic dermatitis market size is segmented on the basis of drugs, route of administration, therapy, end users and geography.

On the basis of drug type, the global atopic dermatitis market is segmented as

• Anti-inflammatory agents
• Antihistamines
• Immunosuppressant
• Interleukin Inhibitors
• Topical Phosphodiesterase (PDE-4)
• Antiviral Agents
• Antibiotics

On the basis of route of administration, the global atopic dermatitis market is segmented as

• Oral
• Injectable
• Topical

On the basis of therapy type, the global atopic dermatitis market is segmented as

• Photo Therapy
• Directed Therapy

On the basis of end users, the global atopic dermatitis market is segmented as

• Hospitals
• Research Lab
• Clinics

Geographically, the global atopic dermatitis market size is categorized into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa.

Rising market consolidations by the leading manufacturers is expected to boost global atopic dermatitis market size in North America.

On the basis of geography, North America is expected to dominate the global atopic dermatitis market size over forecast period. The primary factors influencing growth of atopic dermatitis market size in this region are continuous new product development by the manufacturers, and mergers & acquisitions between manufacturers for covering the untapped market. While, Europe holds the second largest share in atopic dermatitis market size owing to improved medical infrastructure for treating atopic dermatitis.

However, Asia Pacific is estimated to grow at a faster rate during the forecast period. Increasing awareness for the use of biological agents as the treatment of atopic dermatitis, and increased focus of manufacturers on the untapped market is driving the atopic dermatitis market in this region.

Key players in the global atopic dermatitis market are:

• Novartis International AG.
• Pfizer Inc.
• Sonafi SA
• Galderma SA
• Allergen plc.
• Connectics Corporation
• Fujisawa Healthcare
• Encore Dermatology Inc.
• Velite Pharmaceuticals
• Biofrontera AG
• Hoffmann-La Roche AG
• GlaxoSmithKline plc.
• Regeneron Pharmaceuticals
• Leo Pharma A/S
• AsteraZeneca